Clinical Trials Logo

Bioavailability clinical trials

View clinical trials related to Bioavailability.

Filter by:

NCT ID: NCT03156712 Completed - Iron-deficiency Clinical Trials

Iron Absorption From Iron-enriched Aspergillus Oryzae

BIEFS
Start date: May 29, 2013
Phase: N/A
Study type: Interventional

Ferrous sulfate is rapidly absorbed and the bolus of iron enters blood rather quickly possibly leading to higher concentrations of non-transferrin bound iron which induces oxidative stress. The objective of this study was to determine how quickly iron enters into blood stream from the iron-enriched Asperigillus oryzae (AspironTM, ASP) in contrast to ferrous sulfate. Seventeen healthy, female subjects (18-35 y) were randomized, double blind, cross-over experimental design with three treatments: 10 mg iron as FeSO4 and ASP as well as 20 mg iron as ASP.

NCT ID: NCT03145259 Completed - Bioavailability Clinical Trials

Evaluation of Bioavailability of Diclofenac Dermal Products

Start date: April 19, 2017
Phase: Early Phase 1
Study type: Interventional

The study will utilize already FDA-approved marketed diclofenac products in healthy adults to generate data for establishing rate of drug delivery comparisons between diclofenac epolamine patches and diclofenac sodium solution in healthy adults and to determine skin concentrations.

NCT ID: NCT02986529 Completed - Bioavailability Clinical Trials

A Study to Assess the Bioavailability of Oral Sodium Oligo-mannurarate (GV-971) in Healthy Chinese Male Subjects

Start date: November 2016
Phase: Phase 1
Study type: Interventional

To evaluate the Bioavailability for GV-971 capsules of 150 mg, 300mg, and 450mg after administration of single oral doses of 900mg in healthy Male subjects.

NCT ID: NCT02712593 Completed - Bioavailability Clinical Trials

A Study Investigating the Effects of Niagen™ in Healthy Adults.

15NRHC
Start date: March 21, 2016
Phase: Phase 2
Study type: Interventional

This study will evaluate the effect of repeated doses of Niagen™ on Niagen™ metabolite concentrations in blood, urine and muscle. There will be 3 doses of Niagen™ compared to a placebo. One quarter of subjects will receive the low dose of Niagen™, one quarter will receive the moderate dose of Niagen™, one quarter will receive the higher dose of Niagen™ and one quarter will reveive the placebo.

NCT ID: NCT02557139 Completed - Bioavailability Clinical Trials

Bioavailability of Belumosudil (KD025) in Healthy Male Subjects

Start date: September 2015
Phase: Phase 1
Study type: Interventional

Phase 1 bioavailability study to evaluate the pharmacokinetics (PK) and tolerability/safety of the belumosudil tablet formulation in the fasted and fed states and compared to the belumosudil capsule formulation in the fed state.

NCT ID: NCT02446171 Completed - Healthy Subjects Clinical Trials

A Bioavailability Study With Alternate Methods of Administration of Naloxegol Tablets, and Solution

Start date: May 2015
Phase: Phase 1
Study type: Interventional

This clinical study is an open-label, randomized, 4-period, 4-treatment, crossover, single-center, single-dose bioavailability study with alternate methods of administration of crushed naloxegol tablets, 25 mg and of a naloxegol solution formulation, 25 mg, compared to whole naloxegol tablets, 25 mg, in healthy subjects. The main objective of this study is to determine the bioavailability of each of three alternative methods of naloxegol administration compared to whole naloxegol tablets given orally by assessment of the primary pharmacokinetic (PK) parameters of naloxegol

NCT ID: NCT02415374 Completed - Metabolism Clinical Trials

Bioavailability and Metabolism of Avenanthramide: a Novel Oat Phytochemical

Start date: January 5, 2015
Phase: N/A
Study type: Interventional

The purpose of the study is to examine whether orally ingested oat avenanthramides (AVA) in oat flour cookies are bioavailable in humans by measuring plasma and urine concentrations of AVAs and their potential metabolites after ingestion. The blood and urine concentrations will be quantified at several different time points after the oat flour cookies are consumed to characterize the "concentration-time profile".

NCT ID: NCT02400333 Completed - Healthy Subjects Clinical Trials

Study to Assess the Bioavailability of Ticagrelor OD Tablet vs. IR Tablet

Start date: June 2015
Phase: Phase 1
Study type: Interventional

This study will be an open-label, randomised, four-period, four-treatment, crossover study in healthy male and female of non-childbearing potential subjects, performed at a single study centre. The objective of the study is to assess the bioavailability of ticagrelor orodispersible (OD) tablets when administered with water, without water and suspended in water to be administered through nasogastric tubes, compared to ticagrelor immediate-release (IR) tablets.

NCT ID: NCT02221791 Completed - Clinical trials for Endothelial Dysfunction

Comparison of Pure Epicatechin and Cocoa on Markers of Vascular Function

FLAVO2
Start date: June 2014
Phase: N/A
Study type: Interventional

Intervention studies support a protective effect of flavonoid-rich foods such as chocolate and tea on cardiovascular disease risk. In a previous study we found that pure epicatechin improves markers of vascular function and insulin resistance although the results were less pronounced than the majority of chocolate intervention studies. The food matrix of chocolate or other compounds present in chocolate could play a role in the bioavailability of flavonoids, resulting in these heightened improvements in vascular function. In this study we aim to compare the acute effects of pure epicatechin and high-flavonoid chocolate on markers of vascular function.

NCT ID: NCT02138396 Completed - Bioavailability Clinical Trials

Exploratory Bioavailability of Fentanyl Sublingual Spray Under Fasting Conditions

Start date: January 2014
Phase: N/A
Study type: Interventional

The objective of this study is to compare the rate of absorption and bioavailability of fentanyl sublingual spray 400 mcg to fentanyl citrate 100 mcg by intramuscular injection.